S&P 500
7,590.00
-0.16%
Dow Jones
50,870.20
-0.40%
Nasdaq 100
30,483.20
-0.03%
Russell 2000
2,902.01
+0.01%
FTSE 100
10,373.60
+0.36%
Nikkei 225
66,724.20
-0.75%

Health and Healthcare

Another Boost For Threshold (THLD)

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) has been one of the top performing stocks of 2012.  Not just in emerging pharma and in biotech, but across the board.  Now we have some more good news of an orphan drug designation being granted out of Europe.

The European Commission has granted an Orphan Drug Designation for the company’s TH-302, a hypoxia-targeted drug for the treatment of soft tissue sarcoma.  Soft tissue sarcoma is an aggressive form of cancer for which there is a significant unmet medical need.

The company noted that TH-302 was designed “to selectively target hypoxic regions within tumors, which are believed to not be effectively treated with current therapy.”

Keep in mind that Threshold shares were well under $2.00 at the start of 2012. Shares closed on Thursday at $6.73.  This stock has traded in a range of $1.18 to $7.50 over the last year and its market capitalization rate is $330 million.

JON C. OGG

Follow 24/7 Wall St. on Google
Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. www.247wallst.com.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

This $2.5 Million Portfolio Delivers $14,500 a Month With Three Income Buckets
Drew Wood |

This $2.5 Million Portfolio Delivers $14,500 a Month With Three Income Buckets
Want to Retire In a Tropical Caribbean Paradise on Social Security Only? Here's How.
Drew Wood |

Want to Retire In a Tropical Caribbean Paradise on Social Security Only? Here's How.

Continue Reading

Jon C. Ogg |

Biotech Stocks Under $10 With Huge Upside Potential for 2014

24/7 Wall St. ran a screen of the Wall Street firms we cover looking for biotech stocks trading under $10…

Why Threshold Pharma Is Imploding
Chris Lange |

Why Threshold Pharma Is Imploding

Threshold Pharmaceuticals watched its stock completely collapse in Monday’s session after a joint late-stage study failed to yield positive results.

Clementia Pharmaceuticals Announces Potential Pricing for IPO
Chris Lange |

Clementia Pharmaceuticals Announces Potential Pricing for IPO

Clementia Pharmaceuticals intends to price more than 7 million shares in a range that will result in an initial public…

Chris Lange |

Tracon Pharmaceuticals Surges With Positive Study

Tracon Pharmaceuticals made waves in the market on Friday morning, not so much due to one trial but really one…

Jon C. Ogg |

Five Analyst Stock Picks With 100% or More Implied Upside

This past week we scoured our Wall Street coverage looking for analysts stock picks that have huge upside targets, and…

5 Companies That Absolutely Destroyed Shareholders This Past Week
Chris Lange |

5 Companies That Absolutely Destroyed Shareholders This Past Week

Here are five companies that punished their shareholders this past week, a rough one for the broad markets.

FDA Issues an Approval Not Seen in Almost 20 Years
Chris Lange |

FDA Issues an Approval Not Seen in Almost 20 Years

In an incredible move on Friday, the FDA approved Endari for the treatment of patients age five and older with…

CytRx Crumbles on Late-Stage Whiff
Chris Lange |

CytRx Crumbles on Late-Stage Whiff

CytRx absolutely crumbled in Tuesday’s session after the company released less than favorable late-stage results.

Chris Lange |

Oncolytics Newest Orphan Drug Designation

ThinkstockOncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for Reolysin.…

Top Gaining Stocks

MGM Resorts
MGM • Vol: 27,683,097
CDW
CDW • Vol: 3,240,293
Datadog
DDOG • Vol: 11,190,990
Gartner
IT • Vol: 2,031,591
Dell Technologies
DELL • Vol: 20,848,965

Top Losing Stocks

FedEx
FDX • Vol: 2,399,340
Cboe Global Markets
CBOE • Vol: 2,828,165
Qualcomm
QCOM • Vol: 21,186,645
Coterra Energy
CTRA • Vol: 73,319,495
Constellation Energy
CEG • Vol: 11,480,635